BML Capital Management, LLC 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
BML Capital Management, LLC disclosed 26 US equity positions worth $123.6m in its Q1 2025 13F filing. The largest position was AVIR at 18.4% of the reported book, followed by ACRS and THIRD HARMONIC BIO INC. Against the Q4 2024 filing, it opened 6 new positions, added to 7 and reduced 2 among the top 26 holdings.
What did BML Capital Management, LLC own in Q1 2025? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | AVIR ATEA PHARMACEUTICALS INC | Healthcare | 18.4% | $22.8m | 7,609,812 | 0% | held |
| 2 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 17.6% | $21.8m | 14,250,000 | 0% | held |
| 3 | THIRD HARMONIC BIO INC | 10.7% | $13.3m | 3,824,417 | – | new | |
| 4 | AVU0 ADVERUM BIOTECHNOLOGIES INC | 9.7% | $12.0m | 2,742,317 | 21% | added | |
| 5 | ANTX AN2 THERAPEUTICS INC | 6.3% | $7.8m | 5,749,432 | 0% | held | |
| 6 | TIL INSTIL BIO INC | 5.9% | $7.2m | 416,720 | 4% | added | |
| 7 | EPIEUR ESSA PHARMA INC | 5.4% | $6.7m | 4,221,546 | 0% | held | |
| 8 | ORMP ORAMED PHARMACEUTICALS INC | 5.2% | $6.5m | 3,020,748 | 14% | added | |
| 9 | IKENA ONCOLOGY INC | 3.8% | $4.7m | 3,710,803 | 3% | added | |
| 10 | PMVP PMV PHARMACEUTICALS INC | 3.3% | $4.1m | 3,747,612 | 8% | added | |
| 11 | WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 2.7% | $3.4m | 1,890,245 | -10% | reduced |
| 12 | LAVA THERAPEUTICS NV | 2.0% | $2.5m | 1,960,610 | – | new | |
| 13 | 2KZ0 KEZAR LIFE SCIENCES INC | 1.6% | $2.0m | 408,138 | 739% | added | |
| 14 | ELEVATION ONCOLOGY INC | 1.2% | $1.5m | 5,890,934 | – | new | |
| 15 | ASTROTECH CORP | 1.2% | $1.4m | 220,410 | 0% | held | |
| 16 | CNTB CONNECT BIOPHARMA HLDGS LTD | 0.9% | $1.2m | 2,093,232 | 0% | held | |
| 17 | SG7 SAGE THERAPEUTICS INC | 0.9% | $1.1m | 135,095 | – | new | |
| 18 | ATHIRA PHARMA INC | 0.7% | $911.9k | 3,200,667 | 15% | added | |
| 19 | MIST MILESTONE PHARMACEUTICALS IN | 0.7% | $909.0k | 1,136,091 | 0% | held | |
| 20 | LSTA LISATA THERAPEUTICS INC | 0.4% | $509.6k | 216,853 | -24% | reduced | |
| 21 | TURNSTONE BIOLOGICS CORP | 0.4% | $452.4k | 1,103,386 | – | new | |
| 22 | VTGN VISTAGEN THERAPEUTICS INC | 0.3% | $375.0k | 150,000 | 0% | held | |
| 23 | ALMS ALUMIS INC | 0.2% | $304.7k | 49,627 | – | new | |
| 24 | NXTC NEXTCURE INC | 0.1% | $131.4k | 273,536 | 0% | held | |
| 25 | VRCA VERRICA PHARMACEUTICALS INC | 0.1% | $77.2k | 174,651 | 0% | held | |
| 26 | HILLEVAX INC | 0.0% | $30.1k | 20,760 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.